PFE trade ideas
paper trading pfe 03 feb 2021Disclaimer:
This information is for educational purposes and is not an investment recommendation or representative of professional expertise. This analysis used herein is for illustration purposes only. This personal opinion should not be considered specific investment advice. I am not responsible for any trades, and individuals are solely responsible for any live trades placed in their own personal accounts.
for today price moving in line channel trading area and price go to $34,16
good luck and happy profit,
LONG PFEPrice retest support line
Potential entry $34.50 and below
Pfizer’s fourth-quarter results were mixed as it missed estimates for earnings while beating the same for sales. Pfizer’s financial outlook for 2021 was quite upbeat.
paper trading pfe 03 feb 2021Disclaimer:
This information is for educational purposes and is not an investment recommendation or representative of professional expertise. This analysis used herein is for illustration purposes only. This personal opinion should not be considered specific investment advice. I am not responsible for any trades, and individuals are solely responsible for any live trades placed in their own personal accounts.
secara daily harga akan bergerak turun ke level 34,09
good luck and happy profit
Pfizer Inc. (PFE)Pfizer reported fourth-quarter earnings of 42 cents per share, below the 50 cents expected by consensus while revenue was 11.7 billion, slightly above expectations of 11.5 billion. The pharmaceutical group, however, surprised the market by indicating that it is witnessing that sales of the anti-covid vaccine produced together with the German BioNTech will generate sales of 15 billion dollars in the 2021 while consensus expectations were steady at 12.7.
Something to Watchi lost first buys at 37 so lets see how this lower zone will act
no confirmation = no trade
no profit margin = no trade
must get a confirmation on LTF
Either 15M Timeframe or 10M or 5M
we must get a change of trend on those timeframes like price coming into the zone with LL/LH and we need HH/HL To come in!
that's how i enter 99% of my trades
PFE bottoming out in channelgood buy opportunity around these levels
so far this channel has been strong, bouncing back and forth from top to bottom
pitchfork confluence as well
not financial advice
Pfizer MT (February 2nd 2021)Pfizer (PFE) (February 2nd 2021 through August 2021)
Low: $32 - $35
High: $42 - $49
2020 Q4 announcements are in a few hours.
Here's a bit of what I'm personally expecting:
Positive guidance for 2021
I don't think the EPS will exceed analyst expectations of $0.51 cents, but if it does, it could land somewhere around $0.70 cents. I think $0.25 is more likely for now, but there's definitely a chance that the 2020 vaccine news could provide the uptick needed to bring it to at least $0.45 to $0.48. Very indecisive for me right now.
I believe that regardless of news, trading today could close positively from its open.
I haven't spent a ton of time on this chart and have only started to look into the specifications that the new vaccines are providing. Definitely a good watch for the future. I cannot fully say this will be bullish or bearish in the long term as of right now.
Thanks for tuning in :) Disclaimer, anyone in the trade needs to do their own due diligence and decide what is right for YOU. My charts can be wrong at any time and it's very important that you have your own strategies and plans in place. I run this channel for my own educational purposes of learning to trade, and I will never be 100% right, so please do not let me confirm any bias for you! (Dangerous to do so, stay safe and remember the basics & rules of risk assessment.) Expect the unexpected and happy trading!
PFE: Ascending Channel$PFE - Ascending Channel
Targets:
$37.66
$39.76
$41.73
Thank you and Good Luck!
PFE earnings could break downtrend this ones a gamble but im very confident that pfizer will have a nice earnings report from their covid vaccine
$PFEDaily hidden bullish divergence on the MACD and RSI
Stop = Below support
Target = Resistance @ around $41
PFizer D1The disease statistics for the Coronavirus in the world has reached the level of 1,000,000 population. This situation creates enormous problems for the economy and for the life of people in general. But for the PFizer company, this just gives a huge potential for the possibility of earning money on this problem. Because the market has a huge potential for sales. And the bulk of people will be vaccinated with this particular vaccine. And this will be government procurement, which will amount to millions of dollars in revenue for the company. Which will stimulate stocks to grow.
Phizer pulling back nicely to support trendlineShares of Phizer (NYSE:PFE) are pulling back nicely to the trendline going back to March of last year. The share is also touching its 200MA. Results are due on Tuesday next week so Im keeping a close eye on this one. If we get a bounce the share could be on its way back to previous highs reached in November 2018, given a potential return of 20% over the coming year. As a bonus, the share is also a good dividend payer. Pfizers contribution to the vaccine and Covid fight should also provide some long term support.
Looks like PFE it's going to break upFrom the technical point of view, if PFE breaks the resistance level noted in this chart it can go easily over 40$ USD after earnings.
There's no reason to short Pfizer right now. The company got massive amount of money from vaccine pre-orders, investments and probably the earnings will be at last at estimated level.
Pfizer forming a double bottom to continue moving up?Another update on PFE. Price has stalled for some time now around the internal support. We have a divergence with RSI and the price and RSI is starting to move above 50. MACD is making a bullish crossing and the histogram is going positive as well. Volumes are showing buying activity and we have a potential setup for a double bottom. Keep an eye on PFE.
Myovant Sciences and Pfizer Announce Positive One-Year Data fromMYOV,PFE: Myovant Sciences, Inc.
2021-01-26 06:55:00
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
